In vitro models

  • Primary cell cultures
  • Cancer cell lines (lymphoma, glioblastoma, breast cancer, colon cancer, lung cancer and other customizable models).
  • Tissue cultures
  • Injury models

 

In vitro screening assays

  • Immunophenotyping
  • Gene expression profiling (mRNA)
  • microRNA profiling (miRNA)
  • Transcribed ultraconserved non-conding RNA profiling (T-UCRs)
  • Proliferation assays
  • Cellular functional profiling (ELISPOT/FLUOROSPOT analysis)

In vivo models

  • Cell line-derived xenograft models (CDX)
  • Syngeneic mouse models
  • Patient-derived xenograft models (PDX)
  • Metastasis models

 

In vivo services

  • Pharmacokinetics
  • Toxicity studies
  • Histopathology
  • Metastasis evaluation

Chimeric Antigen Receptor-T cell therapy R&D services

Chimeric antigen receptor T (CAR-T) cell technology has revolutionized cancer treatment. This technology redirects T cell immune response towards malignant cells, mediating tumor cell death. By engineering specific antigen receptors in patient/donor T cells, it is possible to create personalized and unlimited treatment options for various types of cancer.

  • CAR-T design/expression/function assessment
  • CAR-T Activation
  • CAR-T Specificity
  • CAR-T Cytotoxicity in target and non-target cells
  • CAR-T Exhaustion

© 2023 digital connection | All rights reserved | Privacy policy